Showing 8 ideas for tag "progression"

Goal 2: Reduce Human Disease

Characterizing tissue response to injury

Can we characterize in detail the nature of tissue response to injury, resulting in either aberrant repair or regeneration, to generate predictive algorithms and targetable nodes where manipulation can alter the outcome?

 

Can we characterize tissue remodeling, repair and injury? What processes are involved that lead to outcome X and dependent on various perturbegens, genetics? How do you translate that?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Name of idea submitter and other team members who worked on this idea NHLBI Staff

Voting

13 net votes
22 up votes
9 down votes
Active

Goal 2: Reduce Human Disease

The effects of environmental factors on heart, lung, blood, sleep disease development across the lifespan

How do growth, development, exposure, and behavior affect heart, lung, blood, sleep disease development and outcome throughout the lifespan?

 

How do you improve organ function/capacity during childhood?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Details on the impact of addressing this CQ or CC

Defining earliest elements of disease and strategies for prevention

Feasibility and challenges of addressing this CQ or CC

If we don’t start now, it will never get done
. Challenges:
• Determine if elements of cell aging, including stem cell aging and senescence, affect disease progression and the effectiveness of therapeutic interventions
• Can we develop iPS based or other cell based bioengineered tools to more precisely define cellular and molecular responses to particular exposures?
• How do we identify, prioritize and measure relevant environmental exposures?

Name of idea submitter and other team members who worked on this idea NHLBI Staff

Voting

12 net votes
32 up votes
20 down votes
Active

Goal 2: Reduce Human Disease

UNDERSTANDING PROGRESSIVE FIBROTIC DISEASES TO IDENTIFY NEW THERAPEUTIC TARGETS

Our understanding of the factors driving IPF fibrotic progression remain incompletely understood. To develop effective therapies that arrest and reverse the fibrotic process, we must first identify the critical factors driving the spread of fibrosis. Fibroblastic foci, the sentinel morphologic lesion of IPF, are found at the advancing edge of fibrosis. Fibroblastic foci can be conceptualized as a fibrotic niche. The... more »

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Critical Challenge (CC)

Details on the impact of addressing this CQ or CC

Technologically advanced descriptive studies to create a comprehensive fibroblastic focus atlas are a necessary first step to understand fibrotic progression. The atlas will include: 1) The identification and number of each the cell type in the focus and their interplay. There is considerable heterogeneity among the mesenchymal cells and inflammatory cells within the focus and innovative single cell OMICs technology will be required to define disease-relevant subpopulations of each cell type within the focus. This work requires laser caption microdissection, immunohisotchemical and in situ hybridization techniques to map the location of various cell types within the fibroblastic focus. 2) Extracellular matrix composition and mechanical properties. Currently it is unclear whether the fibroblastic focus is topographically polarized. For example, it is conceivable that the focus may be polarized with cell-dense regions consisting of various cell types in a provisional/wound-like matrix juxtaposed to less cellular regions consisting of more mature mesenchymal cells in a collagen rich matrix. 3) Cytokine levels and oxygen tension. There is a large and expanding literature in several biomedical disciplines that each of these characteristics matter; influencing differentiation, proliferation, metabolism, and migration. Lacking all of these data, it is not surprising that IPF has been such a difficult problem to solve.

Feasibility and challenges of addressing this CQ or CC

Since these will be highly innovative, yet descriptive – funding them through investigator initiated awards reviewed by standing study section is not feasible. They will employ novel emerging techniques including single cell RNA sequencing and single cell mass cytometry to identify heterogeneous cell populations, state of the art proteomic techniques to define matrix composition and cytokine levels within the fibroblastic focus, and atomic force microscopy to map stiffness across the fibroblastic focus. When considering applications, an RFA mechanism makes sense (perhaps a U-series granting mechanism) where the standard criteria are used for review, but innovation accounts for 75% of the total priority score. The idea is that the reviewers’ discussion and score will be heavily weighted towards innovation, i.e. really new ideas or approaches with less emphasis on a detailed critique of the methods to be employed, and the impact of the project in advancing knowledge. Therefore, convening a Special Emphasis Panel (SEP) that is instructed to identify the most highly innovative, high impact projects would be ideal.

Name of idea submitter and other team members who worked on this idea Craig Henke and Peter Bitterman

Voting

-1 net votes
12 up votes
13 down votes
Active

Goal 2: Reduce Human Disease

Predicting and monitoring atherosclerosis progression and vulnerable plaque

How to develop novel methods for predicting and monitoring atherosclerosis progression and vulnerable plaque including biomarkers and imaging?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Name of idea submitter and other team members who worked on this idea Society for Vascular Surgery

Voting

3 net votes
4 up votes
1 down votes
Active

Goal 2: Reduce Human Disease

Medical therapy to reduce aneurysm progression

How to develop effective medical therapies to reduce aneurysm progression - currently only surgical intervention is effective.

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Name of idea submitter and other team members who worked on this idea Society for Vascular Surgery

Voting

2 net votes
3 up votes
1 down votes
Active

Goal 2: Reduce Human Disease

Asymptomatic carotid artery disease

What is the most effective approach to asymptomatic carotid artery disease to reduce the burden of stroke?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Details on the impact of addressing this CQ or CC

­Develop improved understanding of factors associated with carotid plaque progression and the reliable identification of higher risk asymptomatic lesions. This will lead to improved selection of asymptomatic patients for carotid intervention, a critical area of controversy and a highly prevalent condition.

Name of idea submitter and other team members who worked on this idea Society for Vascular Surgery

Voting

2 net votes
3 up votes
1 down votes
Active

Goal 2: Reduce Human Disease

Defining the developmental abnormalities leading to birth defects

Can we define the developmental abnormalities leading to birth defects and extrapolate that knowledge to define strategies for regeneration?

 

How can we recognize initiation of disease earlier?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Name of idea submitter and other team members who worked on this idea NHLBI Staff

Voting

-1 net votes
8 up votes
9 down votes
Active

Goal 2: Reduce Human Disease

Extending gene editing and iPS/cell technologies to high throughput formats

Can we extend gene editing and iPS/cell technologies to high throughput formats for the evaluation of genetic variants identified from GWAS in the development and progression of disease?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Name of idea submitter and other team members who worked on this idea NHLBI Staff

Voting

-15 net votes
3 up votes
18 down votes
Active